Journal article · 2016 · Open access

Axitinib blocks Wnt/β-catenin signaling and directs asymmetric cell division in cancer

Yi Qu, Naouel Gharbi, Yuan Xing, Jan Roger Olsen, Pernille Blicher, Bjørn Dalhus, Karl Albert Brokstad, Biaoyang Lin, Anne Margrete Oyan, Weidong Zhang, Karl‐Henning Kalland, Xisong Ke

Proceedings of the National Academy of Sciences, 113(33), 9339–9344 · Published 1 August 2016 · DOI 10.1073/pnas.1604520113

Open full textView at the publisherCite this paper

In brief

“Axitinib blocks Wnt/β-catenin signaling and directs asymmetric cell division in cancer” is a 2016 journal article by Yi Qu and 11 co-authors, published in Proceedings of the National Academy of Sciences. OpenAlex counts 126 citations as of 21 November 2026. It is open access: the full text is free to read at PubMed Central.

Citations
126
Most cited in
2024 (26)
Field-weighted impact
3.00
References
47
Authors
12

Abstract

Oncogenic mutations of the Wnt (wingless)/β-catenin pathway are frequently observed in major cancer types. Thus far, however, no therapeutic agent targeting Wnt/β-catenin signaling is available for clinical use. Here we demonstrate that axitinib, a clinically approved drug, strikingly blocks Wnt/β-catenin signaling in cancer cells, zebrafish, and Apc(min/+) mice. Notably, axitinib dramatically induces Wnt asymmetry and nonrandom DNA segregation in cancer cells by promoting nuclear β-catenin degradation independent of the GSK3β (glycogen synthase kinase3β)/APC (adenomatous polyposis coli) complex. Using a DARTS (drug affinity-responsive target stability) assay coupled to 2D-DIGE (2D difference in gel electrophoresis) and mass spectrometry, we have identified the E3 ubiquitin ligase SHPRH (SNF2, histone-linker, PHD and RING finger domain-containing helicase) as the direct target of axitinib in blocking Wnt/β-catenin signaling. Treatment with axitinib stabilizes SHPRH and thereby increases the ubiquitination and degradation of β-catenin. Our findings suggest a previously unreported mechanism of nuclear β-catenin regulation and indicate that axitinib, a clinically approved drug, would provide therapeutic benefits for cancer patients with aberrant nuclear β-catenin activation.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Qu, Y., Gharbi, N., Xing, Y., Olsen, J. R., Blicher, P., Dalhus, B., Brokstad, K. A., Lin, B., Oyan, A. M., Zhang, W., Kalland, K., & Ke, X. (2016). Axitinib blocks Wnt/β-catenin signaling and directs asymmetric cell division in cancer. Proceedings of the National Academy of Sciences, 113(33), 9339–9344. https://doi.org/10.1073/pnas.1604520113

MLA 9

Qu, Yi, et al. “Axitinib blocks Wnt/β-catenin signaling and directs asymmetric cell division in cancer.” Proceedings of the National Academy of Sciences, vol. 113, no. 33, 2016, pp. 9339–9344. https://doi.org/10.1073/pnas.1604520113.

Chicago

Qu, Yi, Naouel Gharbi, Yuan Xing, Jan Roger Olsen, Pernille Blicher, Bjørn Dalhus, Karl Albert Brokstad, et al. 2016. “Axitinib blocks Wnt/β-catenin signaling and directs asymmetric cell division in cancer.” Proceedings of the National Academy of Sciences 113 (33): 9339–9344. https://doi.org/10.1073/pnas.1604520113.

Harvard

Qu, Y. et al. (2016) ‘Axitinib blocks Wnt/β-catenin signaling and directs asymmetric cell division in cancer’, Proceedings of the National Academy of Sciences, 113(33), pp. 9339–9344. doi:10.1073/pnas.1604520113.

IEEE

Y. Qu et al., “Axitinib blocks Wnt/β-catenin signaling and directs asymmetric cell division in cancer,” Proceedings of the National Academy of Sciences, vol. 113, no. 33, pp. 9339–9344, 2016, doi: 10.1073/pnas.1604520113.

BibTeX

@article{qu2016axitinib,
  title     = {{Axitinib blocks Wnt/β-catenin signaling and directs asymmetric cell division in cancer}},
  author    = {Qu, Yi and Gharbi, Naouel and Xing, Yuan and Olsen, Jan Roger and Blicher, Pernille and Dalhus, Bjørn and Brokstad, Karl Albert and Lin, Biaoyang and Oyan, Anne Margrete and Zhang, Weidong and Kalland, Karl‐Henning and Ke, Xisong},
  journal   = {Proceedings of the National Academy of Sciences},
  year      = {2016},
  volume    = {113},
  number    = {33},
  pages     = {9339--9344},
  doi       = {10.1073/pnas.1604520113},
  url       = {https://doi.org/10.1073/pnas.1604520113}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
201766
20181515
201999
20201313
20211515
20221414
20231111
20242626
20251313
202633

Its field-weighted citation impact is 3.00: it has been cited 3.00 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Wnt/β-catenin signaling in development and cancer

  • axitinib
  • Wnt/β-catenin signaling
  • asymmetric cell division
  • E3 ubiquitin ligase
  • drug repurposing
  • ApcMin/+ mice
  • zebrafish
  • cancer therapy

Work with this paper

Most-cited papers in Biochemistry, Genetics and Molecular Biology

All highly cited Biochemistry, Genetics and Molecular Biology papers

Questions about this paper

How do I cite this paper in APA style?

Qu, Y., Gharbi, N., Xing, Y., Olsen, J. R., Blicher, P., Dalhus, B., Brokstad, K. A., Lin, B., Oyan, A. M., Zhang, W., Kalland, K., & Ke, X. (2016). Axitinib blocks Wnt/β-catenin signaling and directs asymmetric cell division in cancer. Proceedings of the National Academy of Sciences, 113(33), 9339–9344. https://doi.org/10.1073/pnas.1604520113

How many times has this paper been cited?

126 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at PubMed Central: sign in and open the full text from this page.

Who wrote this paper?

Yi Qu, Naouel Gharbi, Yuan Xing, Jan Roger Olsen, Pernille Blicher, Bjørn Dalhus, Karl Albert Brokstad, Biaoyang Lin, Anne Margrete Oyan, Weidong Zhang, Karl‐Henning Kalland, Xisong Ke.

What is the DOI of this paper?

10.1073/pnas.1604520113, permanently at https://doi.org/10.1073/pnas.1604520113. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.